Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
The purpose of this study is to study normal and sarcoma cells. To study these cells we need to have human tissue. You will be having or have already had a procedure to remove tissue. We would like to use some of this tissue. We will use it for laboratory studies on the diagnosis,behavior and treatment of sarcoma. We will perform an extensive biochemical and molecular analysis of your tissue. We will only use extra tissue left over after all needed testing has been done. We will also take blood samples before and/or after your procedure to measure biochemical factors that may help us predict the behavior of sarcoma.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma|
- Analyze NMR biochemical and molecular patterns from oligonucleotide, SNP and CGH arrays to identify markers that can provide an objective measure of sarcoma differentiation, cellularity, proliferation, necrosis and apoptosis. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Determine the variability of NMR biochemical and molecular profiles from oligonucleotide, SNP and CGH arrays within different regions of the primary sarcoma. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||June 2002|
|Estimated Study Completion Date:||June 2015|
|Estimated Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|
Sarcoma patients undergoing core biopsy, incisional biopsy or definitive surgical resection for soft tissue masses of extremity, trunk or retroperitoneum
Other: Specimen protocol
The research specimen will be obtained from the residual specimen that would otherwise be discarded per usual hospital procedure.
In this protocol, we plan to identify specific markers from nuclear magnetic resonance (NMR)biochemical and molecular genetic analysis that predict clinical outcome and responsiveness to therapy in patients with soft tissue sarcoma. Although most sarcomas rarely present diagnostic dilemmas because each has consistent morphologic and cytogenetic features that can readily be identified, it is not possible with conventional methods to predict what the clinical outcome will be for each individual patient, or how a given tumor will respond to neoadjuvant therapy. Thus,new methods for assessing the potential of these tumors to recur or metastasize and respond to therapy will result in real benefits for patients with these sarcomas.
|Contact: Samuel Singer, M.D.||212-639-2940|
|United States, New York|
|Memorial Sloan-Kettering Cancer Center||Recruiting|
|new York, New York, United States, 10065|
|Contact: Samuel Singer, M.D. 212-639-2940|
|Principal Investigator: Samuel Singer, M.D.|
|Principal Investigator:||Singer Singer, M.D.||Memorial Sloan-Kettering Cancer Center|